Seres Therapeutics Announces Completion of Enrollment in SER-109 Phase 3 ECOSPOR III Study for Recurrent Clostridium difficile Infection and Provides Clinical Pipeline Updates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 30, 2020-- Seres Therapeutics, Inc., (Nasdaq: MCRB) announced today that the Company has completed enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III. SER-109 is an oral, first-in-field...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials